Berberat Pascal O, A-Rahim Yousif I, Yamashita Kenichiro, Warny Michel M, Csizmadia Eva, Robson Simon C, Bach Fritz H
Immunobiology Research Center, Department of Surgery, Beth Israel Deconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Inflamm Bowel Dis. 2005 Apr;11(4):350-9. doi: 10.1097/01.mib.0000164017.06538.8a.
Heme oxygenase-1 (HO-1) seems to have an important protective role in acute and chronic inflammation. The products of heme catalysis, biliverdin/bilirubin, carbon monoxide (CO), and iron (that induces apoferritin) mediate the beneficial effects of HO-1. Blockade of HO-1 activity results in exacerbation of experimental colitis. We tested whether HO-1 has protective effects in the development of colitis and determined that specific enzymatic products of HO-1 are responsible for these effects.
Colitis was induced by oral administration of dextran sodium sulfate (5%) to C57BL/6 mice for 7 days. HO-1 was up-regulated by cobalt-protoporphyrin (5 mg/kg, intraperitoneally). Biliverdin, exogenous CO, or the iron chelator desferrioxamine was administered to other groups.
Cobalt-protoporphyrin treatment resulted in significant up-regulation of HO-1 protein in mucosal and submucosal cells. Induction of HO-1 was associated with significantly less loss of body weight in mice with induced colitis (-12% versus -22% in the control animals, P < 0.001). Development of diarrhea and gastrointestinal hemorrhage was substantially delayed in animals in which HO-1 was induced, and mucosal injury was significantly attenuated. Administration of CO or desferrioxamine alone had no significant effects, whereas enhanced protection with lesser evidence of bowel inflammation was observed with systemic biliverdin administration (50 micromol/kg, 3 times per day, intraperitoneally).
We conclude that heightened HO-1 expression or administration of biliverdin ameliorates dextran sodium sulfate-induced experimental colitis. Novel therapeutic strategies based on HO-1 and/or biliverdin administration may have use in inflammatory bowel disease.
血红素加氧酶-1(HO-1)似乎在急性和慢性炎症中发挥重要的保护作用。血红素催化产物胆绿素/胆红素、一氧化碳(CO)和铁(诱导脱铁铁蛋白)介导HO-1的有益作用。阻断HO-1活性会导致实验性结肠炎恶化。我们测试了HO-1在结肠炎发展过程中是否具有保护作用,并确定HO-1的特定酶促产物是造成这些作用的原因。
给C57BL/6小鼠口服5%葡聚糖硫酸钠7天以诱导结肠炎。通过腹腔注射钴原卟啉(5mg/kg)上调HO-1。向其他组给予胆绿素、外源性CO或铁螯合剂去铁胺。
钴原卟啉治疗导致黏膜和黏膜下细胞中HO-1蛋白显著上调。HO-1的诱导与诱导性结肠炎小鼠体重显著减轻较少相关(-12%对对照组动物的-22%,P<0.001)。HO-1被诱导的动物腹泻和胃肠道出血的发生显著延迟,黏膜损伤显著减轻。单独给予CO或去铁胺没有显著影响,而腹腔内每天3次给予系统性胆绿素(50μmol/kg)观察到增强的保护作用且肠道炎症证据较少。
我们得出结论,HO-1表达升高或给予胆绿素可改善葡聚糖硫酸钠诱导的实验性结肠炎。基于HO-1和/或给予胆绿素的新型治疗策略可能对炎症性肠病有用。